ArticleInflammopharmacology2025
Immunomodulatory properties of a methanolic extract of Ficus lyrata mitigate inflammation in Complete Freund's Adjuvant-induced arthritis.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ficus virens in neurotherapeutics: bridging ethnomedicinal evidence with Nrf2/Keap1 and neuroinflammatory mechanisms.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ficus lyrata, renowned for its traditional use in alleviating rheumatic pain and inflammation, was validated for its purported anti-arthritic and antiinflammatory properties using InvivoandInvitromodels. In the in-vivo studies, carrageenan-induced acute oedema and a chronic arthritis induced by complete Freund's adjuvant (CFA) were employed. Oral dosing of methanolic extract from Ficus lyrata (m-FL) was administered at (250,500 and 750 mg/kg) as well as methotrexate at 1 mg/kg, significantly (p < 0.0001) demonstrated a dose dependent decrease in percent oedema/inflammation and notably reduced arthritis development in the CFA model, indicating strong anti-inflammatory effects over time. Further analysis revealed m-FL extract inhibited protein denaturation across all evaluated concentrations(1600,800,400,200,100,50 µg/ml) suggesting potential mechanisms for their anti-inflammatory action. Phytochemical analysis identified flavonoids and phenolic compounds in the extract. Gene expression analysis of m-FL extract treatment group using qPCR showed a significant (p < 0.0001) downregulation of various inflammatory markers (IL1,COX2,IL1β, NFκB, TNF,STAT-3,IL6) with simultaneous upregulation in the expression of antiinflammatory markers (IL4,10). The m-FL extract targets TNF-mediated decrease in interleukins specifically IL-1, IL1β and IL-6. Histopathological assessments and radiographic evaluations conducted subsequently demonstrated a significant decline in joint inflammation, bone erosion, and pannus formation, along with improved bone integrity and reduced inflammation in the m-FL extract-treated groups (p < 0.0001). Although the m-FL extract exhibited relatively stronger antioxidant activity compared to ascorbic acid in-vitro, the primary efficacy lies in the potent immunomodulatory and anti-arthritic effects. The m-FL extract showed potential as an adjunct therapy for managing inflammatory conditions.
Indexed as
Identifiers
40140117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.